Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 4/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319210 | 1.00 | NQO2 (0.50) | NQO2PTGS1PTGS2NR1I2CES2 | |
| SCHEMBL6319206 | 1.00 | NQO2 (0.50) | NQO2PTGS1PTGS2NR1I2CES2 | |
| SCHEMBL24738797 | 0.84 | NQO2 (0.43) | NQO2PTGS1PTGS2NR1I2CES2 | |
| SCHEMBL26093064 | 0.84 | NQO2 (0.49) | NQO2PTGS1PTGS2NR1I2CES2 | |
| SCHEMBL28062355 | 0.83 | KDM4E (0.53) | NQO2NR1I2CES2CES1MAPT | |
| SCHEMBL14604996 | 0.81 | NR1I2 (0.53) | NQO2PTGS1PTGS2NR1I2CES2 | |
| SCHEMBL29047156 | 0.78 | GPR52 (0.59) | CES2CES1MAPTALDH1A1 | |
| SCHEMBL6433983 | 0.77 | CES2 (0.51) | NR1I2CES2CES1MAPTKDM4E | |
| SCHEMBL29633520 | 0.76 | TBXAS1 (0.41) | — | |
| SCHEMBL5078621 | 0.76 | NQO2 (0.60) | NQO2PTGS1PTGS2NR1I2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | NQO2 3433/4885PTGS1 1821/4885PTGS2 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.